Wendy King, APRN
Family · Laramie, WYNPI 1235210451
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 245 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$501
- AstraZeneca$481
- Otsuka America Pharmaceutical, Inc.$394
- Lundbeck LLC$378
- Vanda Pharmaceuticals Inc.$375
- Lilly USA, LLC$223
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,31398%
- Education$1062%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $501 |
| AstraZeneca | 27 | $481 |
| Otsuka America Pharmaceutical, Inc. | 21 | $394 |
| Lundbeck LLC | 24 | $378 |
| Vanda Pharmaceuticals Inc. | 23 | $375 |
| Lilly USA, LLC | 13 | $223 |
| GSK | 13 | $216 |
| Sunovion Pharmaceuticals Inc. | 12 | $183 |
| Corium, LLC | 12 | $181 |
| Novo Nordisk | 11 | $179 |
| Alkermes, Inc. | 9 | $178 |
| Exact Sciences | 9 | $169 |
| AbbVie | 7 | $128 |
| Teva Pharmaceuticals USA, Inc. | 2 | $117 |
| Amgen | 6 | $111 |
| Neurocrine Biosciences, Inc. | 4 | $110 |
| Pfizer | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $78 |
| Alfasigma USA, Inc. | 4 | $72 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Dexcom, Inc. | 2 | $53 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Merck | 1 | $19 |
| Novartis | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
How this compares
$4,419 in reported general payments places this provider in the 95th percentile of 284 family providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 18 | $67,567 |
| MounjaroTirzepatide | 37 | $38,974 |
| TrulicityDulaglutide | 33 | $38,139 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $27,118 |
| EliquisApixaban | 24 | $22,244 |
| OzempicSemaglutide | 19 | $16,912 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $16,527 |
| XareltoRivaroxaban | 20 | $16,115 |
| FarxigaDapagliflozin Propanediol | 12 | $10,697 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,231 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,393 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $6,037 |
| Atorvastatin Calcium | 193 | $2,721 |
| Bupropion XlBupropion Hcl | 64 | $2,661 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $2,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $223 | $77,862100 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $216 | $43,64573 claims |
| PfizerEliquis | $83 | $22,24424 claims |
| Novo NordiskOzempic | $179 | $16,91219 claims |
| AstraZenecaFarxiga | $481 | $10,69712 claims |
| AbbVieSynthroid | $128 | $1,36213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 284 family providers in Wyoming.
Other family in Laramie
- Peggy HarrisLaramie$4K
- Kelly PlessmanLaramie$3K
- Nancy HalseyLaramie$1K
- Tabitha MarisLaramie$1K
- Jill GiranyCheyenne$44K
- Brenna KirschGillette$14K
- Debra GrinerCasper$9K
- Kelly EckesCasper$7K
- Jamie MosbruckerCasper$6K
- Kathryn HeimerCheyenne$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.